The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 15, 2014
Filed:
Oct. 12, 2007
Miles Stuart Congreve, Melbourn, GB;
Lynsey Helen Fazal, Cambridge, GB;
Martyn Frederickson, Cambridge, GB;
Christopher William Murray, Cambridge, GB;
Michael Alistair O'brien, Hitchin, GB;
Andrew James Woodhead, Cambridge, GB;
John Francis Lyons, Cambridge, GB;
Neil Thomas Thompson, Cambridge, GB;
Miles Stuart Congreve, Melbourn, GB;
Lynsey Helen Fazal, Cambridge, GB;
Martyn Frederickson, Cambridge, GB;
Christopher William Murray, Cambridge, GB;
Michael Alistair O'Brien, Hitchin, GB;
Andrew James Woodhead, Cambridge, GB;
John Francis Lyons, Cambridge, GB;
Neil Thomas Thompson, Cambridge, GB;
Astex Therapeutics Limited, Cambridge, GB;
Abstract
The invention provides a compound for use in medicine, the compound being a compound of the formula (VI) or a salt, solvate, tautomer or N-oxide thereof: wherein the bicyclic group: is selected from the structures C1, C5 and C6: wherein n is 0, 1, 2 or 3; Ris hydrogen, hydroxy, or O—R; Ris hydroxy, methoxy or O—R; provided that at least one of Rand Ris O—R; Ris L-R; SOH; a glucuronide residue; a mono-, di- or tripeptide residue; or Lis a bond, C═O, (C═O)O, (C═O)NRor S(O)NR; x is 1 or 2; Ris hydrogen or a an optionally substituted Chydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that Ris not hydrogen when Lis a bond, C═O or (C═O)O; and provided also that O—Rdoes not contain an O—O moiety; and excluding compounds wherein Ris hydroxy and Ris methoxy; Rand Rare the same or different and each is a group R; and R, R, Rand Rare defined in the claims. The compounds of formula (VI) are pro-drugs of parent compounds wherein Rand/or Rare hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.